Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals chairman Douglass Given to retire from board December 31

Neutral Impact 3 of 5 leadership Written later

Chairman Douglass Given tendered his retirement from the Arrowhead Pharmaceuticals board, effective December 31, 2024, after serving 14 years. The company expects Sarepta Therapeutics CEO Douglas S. Ingram to join the board in the first quarter of 2025, at the closing of their license and collaboration agreement dated November 25, 2024.

Key points

  • Douglass Given tendered his retirement on December 11, 2024, effective December 31, 2024
  • Given served 14 years on the board and was serving as Chairman and a member of the Science Committee
  • Douglas S. Ingram, President and CEO of Sarepta Therapeutics, expected to join the board in Q1 2025, concurrent with the Sarepta agreement closing

The filing

CompanyArrowhead Pharmaceuticals (ARWR)
Form8-K, current report
Filed with the SECDec 17, 2024, 5:38 PM ET
Accession number0001628280-24-051729

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:17 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 17, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.